Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

PubWeight™: 1.56‹?› | Rank: Top 4%

🔗 View Article (PMC 2614443)

Published in Am J Ophthalmol on June 25, 2008


John H Kempen1, Sapna Gangaputra, Ebenezer Daniel, Grace A Levy-Clarke, Robert B Nussenblatt, James T Rosenbaum, Eric B Suhler, Jennifer E Thorne, C Stephen Foster, Douglas A Jabs, Kathy J Helzlsouer

Author Affiliations

1: Ocular Inflammation Service, Scheie Eye Institute, The University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. john.kempen@uphs.upenn.edu

Articles citing this

Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol (2009) 2.33

Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23

Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75

Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int (2011) 1.64

Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58

Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44

Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41

Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond) (2011) 1.10

Emerging drugs for uveitis. Expert Opin Emerg Drugs (2011) 1.08

Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology (2012) 0.97

[Anti-TNF-α treatment for uveitis. Analysis of the current situation]. Ophthalmologe (2011) 0.90

Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study. Ophthalmology (2015) 0.89

Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect (2011) 0.87

Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. Am J Ophthalmol (2011) 0.86

Success with single-agent immunosuppression for multifocal choroidopathies. Am J Ophthalmol (2014) 0.86

Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys. Transplantation (2014) 0.84

Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation. Am J Ophthalmol (2012) 0.83

Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol (2011) 0.82

Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol (2014) 0.81

Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol (2011) 0.80

Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis. Clin Ophthalmol (2011) 0.79

Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease. Clin Ophthalmol (2009) 0.79

Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy. Invest Ophthalmol Vis Sci (2011) 0.78

Systemic lupus erythematosus, pregnancy and carcinoma of the tongue. BMJ Case Rep (2013) 0.77

Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis (2016) 0.76

Treatment of uveitis: beyond steroids. Indian J Ophthalmol (2009) 0.75

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner. Cell Death Dis (2017) 0.75

Remission of Intermediate Uveitis: Incidence and Predictive Factors. Am J Ophthalmol (2016) 0.75

[Monitoring treatment with biologics in non-infectious uveitis]. Ophthalmologe (2011) 0.75

Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol (2015) 0.75

Articles cited by this

Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 15.65

Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol (2000) 4.70

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57

Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet (1998) 3.77

Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 3.25

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum (2007) 3.16

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol (1996) 2.44

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43

Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol (2000) 2.36

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis (2005) 2.25

Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst (1987) 2.12

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum (2007) 2.10

Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation (1990) 2.07

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet (1994) 2.04

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol (2003) 1.91

Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum (1997) 1.86

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum (1995) 1.78

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst (1995) 1.74

Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.74

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis (2007) 1.68

Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst (1995) 1.66

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum (2006) 1.64

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation (2005) 1.62

The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis (1983) 1.61

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.59

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 1.58

Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum (1989) 1.58

Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol (1996) 1.54

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med (1981) 1.52

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs (2002) 1.52

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant (2004) 1.50

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther (2002) 1.41

The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res (2003) 1.37

Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med (1987) 1.26

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2005) 1.25

Aggressive treatment for postcardiac transplant lymphoproliferation. Blood (1995) 1.20

Cyclophosphamide and malignancy. Lancet (1977) 1.15

The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum (1999) 1.13

Second neoplasm--a complication of cancer chemotherapy. N Engl J Med (1977) 1.11

The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis (1982) 1.09

Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transplant (2007) 1.08

The effect of immunosuppression on pre-existing cancers. Transplantation (1993) 1.08

Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation (2001) 1.08

Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA (1975) 1.06

De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer (1997) 1.06

Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis (1995) 1.05

Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol (1991) 1.04

Prednisone and prednisolone in ocular disease. Am J Ophthalmol (1956) 1.04

Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol (2000) 1.04

No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum (1998) 1.03

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology (1996) 1.03

Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 1.01

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene (2007) 1.01

p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status. Oncogene (1997) 1.00

Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med (1988) 0.99

Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc (2004) 0.98

Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl (2002) 0.97

Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation (2003) 0.96

The incidence of bladder cancer after cyclophosphamide therapy. J Urol (1979) 0.96

The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol (2005) 0.95

Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer (2005) 0.95

Long-term experience with low dose methotrexate in rheumatoid arthritis. Rheumatol Int (1993) 0.94

Non-lymphoid cancer after liver transplantation. Hepatogastroenterology (1997) 0.94

Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. J Biol Chem (2000) 0.93

Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol (1990) 0.93

Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis (2001) 0.91

Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res (2007) 0.90

The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation (2000) 0.90

Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant (2005) 0.89

The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol (1988) 0.84

Review of United States data on neoplasms in rheumatoid arthritis. Am J Med (1985) 0.84

No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol (2005) 0.84

Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology (1995) 0.83

The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells. Clin Exp Immunol (2003) 0.83

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA (2006) 0.83

Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc (2006) 0.83

Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treat Rep (1978) 0.83

Genotoxic potential of cyclosporin A in patients with renal transplantation. Cell Biol Toxicol (1999) 0.81

Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica (1983) 0.81

Mutagenicity of cyclosporine. Induction of sister chromatid exchange in human cells. Transplantation (1986) 0.80

One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. Clin Transpl (2000) 0.79

Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation (1999) 0.77

[Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences]. Urologe A (1984) 0.77

Absence of genotoxic potential for cyclosporine in experimental systems. Transplant Proc (1988) 0.77

Cyclosporin abrogates virus-specific T-cell control of EBV-induced B-cell lymphoproliferation. Viral Immunol (1990) 0.77

Malignancy in organ transplantation: heart. Transplant Proc (2002) 0.76

Articles by these authors

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol (2005) 13.50

Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75

The built environment and obesity. Epidemiol Rev (2007) 7.00

TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med (2007) 5.41

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95

C-reactive protein and the risk of incident colorectal cancer. JAMA (2004) 4.94

Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63

Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol (2010) 3.51

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol (2005) 3.50

Childhood uveitis-young patients, old problems, new perspectives. J AAPOS (2008) 3.12

Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum (2007) 3.11

Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol (2008) 2.90

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology (2004) 2.63

Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol (2010) 2.50

Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med (2012) 2.45

Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol (2010) 2.26

Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23

Evaluation of patients with scleritis for systemic disease. Ophthalmology (2004) 2.22

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19

U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18

Plasmapheresis for lupus retinal vasculitis. Arch Ophthalmol (2006) 2.13

The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10

Fruit, vegetable, and antioxidant intake and all-cause, cancer, and cardiovascular disease mortality in a community-dwelling population in Washington County, Maryland. Am J Epidemiol (2004) 2.08

Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst (2008) 2.08

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07

NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology (2007) 2.03

Uveitis in patients with autoimmune hepatitis. Am J Ophthalmol (2009) 2.02

Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol (2005) 2.01

Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology (2011) 2.00

Intraocular lymphoma. Curr Opin Ophthalmol (2002) 1.96

Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol (2010) 1.95

Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94

Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med (2010) 1.88

Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87

The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum (2009) 1.87

Female sexual function and pelvic floor disorders. Obstet Gynecol (2008) 1.86

Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology (2011) 1.85

Identification of a susceptibility locus in STAT4 for Behçet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum (2012) 1.84

The need for standardization of antiretinal antibody detection and measurement. Am J Ophthalmol (2008) 1.83

The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol (2010) 1.83

A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev (2003) 1.80

Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78

Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75

The impact of anemia on energy and physical functioning in individuals with AIDS. Arch Intern Med (2005) 1.75

Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.75

Sympathetic ophthalmia: what have we learned? Am J Ophthalmol (2009) 1.73

C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer (2008) 1.71

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70

Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol (2009) 1.69

Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology (2005) 1.69

Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea (2009) 1.69

Relapsing polychondritis: a clinical review. Semin Arthritis Rheum (2002) 1.68

Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol (2007) 1.66

Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology (2007) 1.66

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun (2003) 1.66

Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis. BMC Genomics (2009) 1.64

Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm (2010) 1.62

Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61

Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58